01.31.17
CPhI Worldwide’s expert panel recently predicted pharma’s biggest opportunities and threats in 2017. The panel forecasts that with the traditional blockbuster drug era widely considered to have passed, orphan drugs and neglected diseases are, in the short-term, likely to deliver pharma’s best revenue opportunities. Over the medium-term, developing world economies and cost reductions from new technologies and working practices like Quality by Design (QbD) and continuous processing should help sustain profits.
Significantly, continuous processing and QbD will also lead a “paradigm shift at instrument companies” with new models, particularly in spectroscopy, specially created for process monitoring and control. “The instrument companies will cooperate with software vendors to produce a more cohesive operating system(s) that will allow multiple instruments to smoothly work in unison for PAT/QbD applications,” said Emil Ciurczak,
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
